🇺🇸 FDA

Intelligence Platform

Patents

Browse 405 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10946009

Combination dosage form of a mu opioid receptor antagonist and an opioid agent

Theravance Biopharma R&D IP, LLC · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10933076

Crocin-sorafenib combination therapy for liver cancer

UNITED ARAB EMIRATES UNIVERSITY · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10918648

Estrogen receptor modulator combinations

The Regents of the University of California · Granted Tue Feb 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10912751

Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of t

Esperion Therapeutics, Inc. · Granted Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10905752

VEGFR-2 targeting DNA vaccine for combination therapy

Vaximm AG · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10905692

Combination therapy for treating malignancies

Agios Pharmaceuticals, Inc. · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10898475

Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions there

VTV THERAPEUTICS LLC · Granted Tue Jan 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10894044

Combination of topoisomerase-I inhibitors with immunotherapy in the treatment of cancer

The Board of Regents of the University of Texas System · Granted Tue Jan 19 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10881666

Combination pharmaceutical agents as RSV inhibitors

Enanta Pharmaceuticals, Inc. · Granted Tue Jan 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10849960

Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovaria

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10835595

PD1 and PDL1 antibodies and vaccine combinations and use of same for immunotherapy

Inovio Pharmaceuticals, Inc. · Granted Tue Nov 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10813909

Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancre

The Regents of the University of California · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10806740

Natural combination hormone replacement formulations and therapies

Compass Therapeutics LLC · Granted Tue Oct 20 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10799584

Combination therapies using agents that target tumor-associated stroma or tumor cells and

THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · Granted Tue Oct 13 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10799512

Estrogen combination for treatment of multiple sclerosis

The Regents of the University of California · Granted Tue Oct 13 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10786552

Il-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 anti

Nektar Therapeutics · Granted Tue Sep 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10780093

Methods of treating brain tumors using combination therapy

Agios Pharmaceuticals, Inc. · Granted Tue Sep 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10765745

Multifunctional nanoparticle systems and methods for cancer diagnosis and combination ther

The Board of Regents of the University of Texas System · Granted Tue Sep 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10758526

Combination therapies using agents that target tumor-associated stroma or tumor cells and

THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · Granted Tue Sep 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10758613

Combination therapies using anti-metabolites and agents that target tumor-associated strom

THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · Granted Tue Sep 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10758614

Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase

THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · Granted Tue Sep 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10729768

Combination of anti-CD20 antibody and PI3 kinase selective inhibitor

TG Therapeutics, Inc. · Granted Tue Aug 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10716782

LPT-723 and immune checkpoint inhibitor combinations and methods of treatment

Biomed Valley Discoveries, Inc. · Granted Tue Jul 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10695352

Combination therapy for treating malignancies

Agios Pharmaceuticals, Inc. · Granted Tue Jun 30 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted